Table 2 Baseline clinical and procedure characteristics of patients stratified by the FAR tertiles
Baseline clinical characteristics | T1 (n = 216) | T2 (n = 219) | T3 (n = 215) | P value |
|---|---|---|---|---|
Age, years | 59.54 ± 10.88 | 62.32 ± 9.59 | 63.01 ± 10.93 | 0.001 |
Sex, male, n (%) | 174 (80.6) | 169 (77.2) | 159 (74.0) | 0.263 |
BMI, kg/m2 | 25.46 ± 3.08 | 25.20 ± 3.35 | 25.19 ± 3.13 | 0.558 |
Heart rate, bpm | 72 (64–81) | 74 (66–82) | 76 (68–86) | 0.003 |
SBP, mmHg | 132.2 ± 17.9 | 131.0 ± 20.7 | 126.5 ± 20.0 | 0.002 |
DBP, mmHg | 81.3 ± 12.6 | 80.3 ± 13.2 | 77.7 ± 13.4 | 0.012 |
Smoking, n (%) | 110 (50.9) | 118 (53.9) | 122(56.7) | 0.480 |
Drinking, n (%) | 39 (18.1) | 50 (22.8) | 37(17.2) | 0.278 |
Hypertension, n (%) | 124 (57.4) | 117 (53.4) | 118(54.9) | 0.700 |
Family history of CAD, n (%) | 27 (12.5) | 23 (10.5) | 21(9.8) | 0.642 |
NT-proBNP, pg/mL | 109.00 (53.53–286.40) | 263.25 (95.99–756.55) | 1020.00(297.85–3054.00) | < 0.001 |
Cardiac troponin T, ng/mL | 0.012 (0.007–0.056) | 0.040 (0.009–0.402) | 0.198(0.015–1.485) | < 0.001 |
Hemoglobin, g/L | 144.87 ± 14.80 | 143.41 ± 15.66 | 136.12 ± 17.54 | < 0.001 |
Platelet, 109/L | 199.80 ± 61.37 | 198.35 ± 49.99 | 218.16 ± 74.84 | 0.016 |
White blood cells, 109/L | 6.89 (5.36–9.08) | 6.81 (5.50–9.40) | 7.59(5.98–9.94) | 0.012 |
Neutrophils, 109/L | 4.82 (3.46–6.60) | 4.86 (3.56–7.00) | 5.47(4.09–7.57) | 0.008 |
Lymphocyte, 109/L | 1.44 (1.07–1.86) | 1.43 (1.11–1.85) | 1.45(1.04–1.87) | 0.853 |
Monocytes, 109/L | 0.32 (0.25–0.41) | 0.34 (0.28–0.44) | 0.42(0.31–0.57) | < 0.001 |
NLR | 3.10 (2.17–4.60) | 3.28 (2.25–5.93) | 3.61(2.51–6.23) | 0.029 |
MLR | 0.22 (0.16–0.28) | 0.24 (0.18–0.32) | 0.29(0.19–0.43) | < 0.001 |
PLR | 131.37 (101.45–171.25) | 134.61 (99.48–179.41) | 140.35(106.66–203.29) | 0.040 |
hs-CRP, mg/L | 0.78 (0.39–1.85) | 1.77 (0.90–3.93) | 5.77(2.86–10.00) | < 0.001 |
ALT, U/L | 25 (18–39) | 27 (18–38) | 26(18–44) | 0.001 |
AST, U/L | 23 (19–33) | 26 (20–57) | 31(20–73) | 0.777 |
Albumin, g/L | 43.44 ± 3.94 | 40.85 ± 3.89 | 37.31 ± 3.94 | < 0.001 |
BUN, mmol/L | 5.69 ± 1.52 | 5.52 ± 1.59 | 5.77 ± 2.18 | 0.390 |
Scr, µmol/L | 67.19 ± 16.91 | 66.10 ± 17.21 | 70.08 ± 23.78 | 0.290 |
Cystatin C, mg/L | 1.006 ± 0.318 | 1.012 ± 0.331 | 1.079 ± 0.326 | 0.033 |
FPG, mg/dL | 4.64 (4.16–5.34) | 4.85 (4.27–5.52) | 4.74(4.18–5.37) | 0.176 |
RBG, mg/dL | 6.30 (5.31–7.84) | 6.35 (5.45–7.73) | 6.11(5.19–7.37) | 0.131 |
eGFR, mL/(min*1.73 m2) | 98.18 (90.43–106.43) | 98.31 (90.76–104.44) | 94.27(84.78–102.40) | 0.001 |
K+, mmol/L | 3.92 ± 0.37 | 3.92 ± 0.39 | 3.94 ± 0.42 | 0.884 |
Na+, mmol/L | 141.33 ± 2.89 | 141.16 ± 3.01 | 140.62 ± 4.13 | 0.281 |
Ca2+, mmol/L | 2.34 ± 0.12 | 2.31 ± 0.15 | 2.25 ± 0.14 | < 0.001 |
Uric acid, µmol/L | 347.16 ± 88.77 | 342.33 ± 87.12 | 331.18 ± 84.60 | 0.148 |
Homocysteine, µmol/L | 16.4 (13.7–22.8) | 17.9 (13.6–23.7) | 18.0 (14.6–24.5) | 0.224 |
PT, s | 13.3 (12.9–13.7) | 13.4 (13.0–13.8) | 13.6 (13.2–14.1) | < 0.001 |
PTA, % | 93.71 ± 12.73 | 92.07 ± 13.69 | 87.03 ± 13.63 | < 0.001 |
INR | 1.03 (0.99–1.07) | 1.03 (0.99–1.07) | 1.06 (1.02–1.11) | < 0.001 |
APTT, s | 35.95 (33.1–38.6) | 36.2 (33.9–39.4) | 37.0 (34.4–40.7) | 0.009 |
TT, s | 16.8 (16.1–17.5) | 16.6 (15.9–17.4) | 16.1 (15.4–17.1) | < 0.001 |
FIB, g/L | 2.66 (2.44–2.92) | 3.33 (3.09–3.51) | 4.10 (3.69–4.77) | < 0.001 |
d-dimer, mg/L | 0.40 (0.30–0.50) | 0.41 (0.30–0.60) | 0.60 (0.40–1.10) | < 0.001 |
FDP, mg/L | 1.00 (0.70–1.30) | 1.20 (0.91–1.50) | 1.60 (1.20–2.70) | < 0.001 |
Triglycerides, mmol/L | 1.37 (1.09–1.92) | 1.30 (0.99–1.88) | 1.17 (0.85–1.63) | < 0.001 |
TC, mmol/L | 3.80 (3.19–4.52) | 3.73 (3.15–4.46) | 3.59 (3.07–4.29) | 0.223 |
LDL, mmol/L | 2.28 (1.70–2.87) | 2.22 (1.68–2.79) | 2.05 (1.65–2.72) | 0.176 |
HDL, mmol/L | 0.93 (0.79–1.09) | 0.91 (0.77–1.07) | 0.90 (0.76–1.02) | 0.138 |
apoA, g/L | 1.136 (1.025–1.240) | 1.083 (0.984–1.228) | 1.035 (0.903–1.162) | < 0.001 |
apoB, g/L | 0.770 (0.630–0.922) | 0.751 (0.629–0.928) | 0.757 (0.617–0.910) | 0.907 |
apoE, g/L | 33.9 (26.0–41.2) | 32.5 (26.6–42.0) | 32.5 (26.7–39.4) | 0.703 |
Lp (a), mg/L | 148 (88–301) | 171 (84–333) | 236 (121–378) | 0.001 |
LVEF, % | 64 (55–69) | 62 (46–69) | 47 (42–63) | < 0.001 |
FAR | 62.80 (57.57–67.66) | 81.46 (77.29–85.28) | 107.14 (97.65–127.86) | < 0.001 |
Gensini score | 52 (34–84) | 62 (40–88) | 72 (48–98) | 0.001 |
Initial diagnosis, n (%) | ||||
UA | 147 (68.1) | 122 (55.7) | 83 (38.6) | < 0.001 |
NSTEMI | 16 (7.4) | 32 (14.6) | 34 (15.8) | 0.017 |
STEMI | 53 (24.5) | 65 (29.7) | 98 (45.6) | < 0.001 |
Killip class, n (%) | ||||
I | 78 (36.1) | 101 (46.1) | 106 (49.3) | 0.016 |
II | 123 (56.9) | 102 (46.6) | 78 (36.3) | < 0.001 |
≥ III | 15 (6.9) | 16 (7.3) | 31 (14.4) | 0.012 |
Diseased vessels number, n (%) | ||||
One-vessel disease | 44 (20.4) | 51 (23.3) | 44 (20.5) | 0.700 |
Two-vessel disease | 69 (31.9) | 49 (22.4) | 49 (22.8) | 0.036 |
Three-vessel disease | 103 (47.7) | 119 (54.3) | 122 (56.7) | 0.148 |
Diseased vessels type, n (%) | ||||
LM | 16 (7.4) | 21(9.6) | 21 (9.8) | 0.632 |
LAD | 202 (93.5) | 199 (90.9) | 208 (96.7) | 0.042 |
LCX | 142 (65.7) | 144 (65.8) | 145 (67.4) | 0.912 |
RCA | 147 (68.1) | 161 (73.5) | 152 (70.7) | 0.457 |
Target vessel territory, n (%) | ||||
LAD | 130 (60.2) | 147 (67.1) | 141 (65.6) | 0.285 |
LCX | 61 (28.2) | 76 (34.7) | 66 (30.7) | 0.340 |
RCA | 113 (52.3) | 103 (47.0) | 98 (45.6) | 0.338 |
Number of stents, n (%) | ||||
1 | 90 (41.7) | 88 (40.2) | 75 (34.9) | 0.316 |
2 | 66 (30.6) | 64 (29.2) | 76 (35.3) | 0.355 |
≥ 3 | 60 (27.8) | 67 (30.6) | 64 (29.8) | 0.803 |
Average length of stents, mm | 27.61 ± 6.29 | 28.60 ± 5.83 | 27.47 ± 6.17 | 0.053 |
Average width of stents, mm | 3.04 ± 0.45 | 2.99 ± 0.39 | 2.91 ± 0.44 | 0.016 |
Plaque property, n (%) | ||||
Calcification lesions | 47 (21.8) | 52 (23.7) | 43 (20.0) | 0.640 |
Diffuse lesions | 56 (25.9) | 60 (27.4) | 55 (25.6) | 0.901 |
Thrombus | 8 (3.7) | 13 (5.9) | 9 (4.2) | 0.505 |
Chronic total occlusions | 25 (11.6) | 31 (14.2) | 37 (17.2) | 0.247 |